Results 171 to 180 of about 47,687 (337)

Cardiovascular Health in Women—Across the Lifespan

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity among women worldwide. However, CVD continues to be perceived as a predominantly male issue. CVD in women therefore remains understudied, underrecognized and undertreated.
Jaya Chandrasekhar   +5 more
wiley   +1 more source

Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Background Older adults with type 2 diabetes (T2DM) are less likely to receive sodium–glucose cotransporter‐2 (SGLT2) inhibitors, despite their proven cardio‐renal benefits and safety. Whether this age‐related gap is driven by frailty, sex, or other factors remains unclear.
Changyuan Yang   +6 more
wiley   +1 more source

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson   +6 more
wiley   +1 more source

On-pump versus off-pump coronary-artery bypass surgery.

open access: yesNew England Journal of Medicine, 2009
A. Shroyer   +8 more
semanticscholar   +1 more source

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan   +7 more
wiley   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino   +14 more
wiley   +1 more source

An oral glucose tolerance test in pregnancy and its association with future cardiovascular diseases

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims/hypothesis Gestational diabetes and abnormal 100‐g oral glucose tolerance test (OGTT) results in pregnancy are associated with type 2 diabetes, but their relationship with cardiovascular disease (CVD) is less clear. We evaluated the risk of CVD according to the number of abnormal OGTT values during pregnancy.
Tal Schiller   +7 more
wiley   +1 more source

Effect of preoperative SGLT2 inhibitor use on postoperative acute kidney injury in patients with type 2 diabetes undergoing surgery: A causal inference study using routinely collected data

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess whether preoperative sodium‐glucose co‐transporter 2 inhibitor (SGLT2i) use reduces the odds of postoperative acute kidney injury (AKI) in patients with type 2 diabetes undergoing surgery. Methods We conducted a target trial emulation using inverse probability of treatment weighting, utilising routinely collected data from a ...
Frank M. Gao   +7 more
wiley   +1 more source

Cost‐Utility Analysis of Left Bundle Branch Area Versus Biventricular Pacing for Cardiac Resynchronization Therapy: A Multicenter, Prospective, Quasi‐Experimental Study

open access: yesJournal of Cardiovascular Electrophysiology, EarlyView.
Cost‐utility of LBBAP CRT versus BVP CRT. ABSTRACT Introduction Cardiac resynchronization therapy (CRT) is a well‐established treatment for patients with heart failure (HF). Recently, left bundle branch area pacing (LBBAP) has emerged as a more physiological alternative to biventricular pacing (BVP) for CRT.
José M. Sánchez‐Moreno   +8 more
wiley   +1 more source

Myocardial Damage and Inflammatory Response After Cardiac Surgical Revascularization on Beating and Arrested Heart. [PDF]

open access: yesBraz J Cardiovasc Surg
Bosnjak A   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy